Fecal Covid-19 test

Offentlig prosjektsammendrag

Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Genetic analysis has a production unit producing reagent kits for the Dysbiosis Test as well as an in-house service laboratory facility. The majority of the scientific staff is however working in a dedicated Research and Development team that constantly improves and develops new products for analysis of the human gut microbiota. This project will build on GAs expertise in human microbiota testing. GA will develop and make available a documented diagnostic assay for SARS-CoV-2 in human fecal samples. Further, GA will explore the impact of intestinal SARS-CoV-2 infection on the long-term health of the patient by identifying predictive microbiota profiles that will be integrated with the GA-map Dysbiosis Test. The knowledge generated and products developed in this project will enable physicians to provide personalized and preventive long-term treatment to Covid-19 patients.